Overall, this report supports the view that FLT3-ITD+ is a strong prognostic factor in AML patients and is associated with low CR, high RR, resistance to therapy, low OS, low DFS and confers a poor prognosis. This evidence concerns the gene FLT3 and acute myeloid leukemia.